Clincosm LogoSign in Get a demo

chronic lymphocytic leukemia

Showing NaN - NaN of 64
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia Trial in United States (drug, procedure, other, radiation)

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • +10 more
  • Jacksonville, Florida
  • +5 more
Aug 14, 2023

Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States

Completed
Has Results
  • Non-Hodgkin's Lymphoma, Relapsed
  • +8 more
  • PBCAR20A
  • +2 more
  • Duarte, California
  • +4 more
Jan 4, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (Ublituximab, Umbralisib, Venetoclax)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Birmingham, Alabama
  • +49 more
Jan 20, 2023

Chronic Lymphocytic Leukemia Trial in Worldwide (Acalabrutinib, Venetoclax, Chemoimmunotherapy)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Fountain Valley, California
  • +201 more
Jan 16, 2023

B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma Trial in Australia, United States (BGB-16673)

Recruiting
  • B-cell Malignancy
  • +8 more
  • Phoenix, Arizona
  • +14 more
Jan 17, 2023

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in United States (Zilovertamab vedotin)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +11 more
  • Zilovertamab vedotin
  • Duarte, California
  • +13 more
Jan 12, 2023

Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Worldwide (Iopofosine I 131 single dose,

Recruiting
  • Waldenstrom Macroglobulinemia
  • +8 more
  • Iopofosine I 131 single dose
  • +2 more
  • Redlands, California
  • +42 more
Dec 30, 2022

Richter Syndrome, Chronic Lymphocytic Leukemia Trial in New York (Polatuzumab Vedotin, Rituximab, Etoposide)

Recruiting
  • Richter Syndrome
  • Chronic Lymphocytic Leukemia
  • Polatuzumab Vedotin
  • +5 more
  • New York, New York
    Weill Cornell Medicine
Dec 19, 2022

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in France, Germany, United States (Odronextamab multiple dose levels)

Recruiting
  • Non-Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Odronextamab multiple dose levels
  • Orange, California
  • +20 more
Dec 14, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome Trial in Italy, United Kingdom, United States

Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Boston, Massachusetts
  • +11 more
Nov 23, 2022

DLBCL, Chronic Lymphocytic Leukemia, B Cell Malignancies Trial in Australia, United States (ABBV-525)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +3 more
  • Louisville, Kentucky
  • +6 more
Nov 14, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (Acalabrutinib, Obinutuzumab)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Basking Ridge, New Jersey
  • +7 more
Nov 9, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Canada, United States (biological, other, drug)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Obinutuzumab
  • +3 more
  • Birmingham, Alabama
  • +484 more
Aug 24, 2022

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in New York (Ibrutinib, Pembrolizumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 22, 2022

Chronic Lymphocytic Leukemia Trial in Boston, Hackensack, New York (Ublituximab, Umbralisib, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Boston, Massachusetts
  • +2 more
Aug 19, 2022

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia Trial in United States (drug,

Recruiting
  • Acute Lymphoblastic Leukemia
  • +7 more
  • Duarte, California
  • +26 more
Aug 11, 2022

Chronic Lymphocytic Leukemia, Hypogammaglobulinemia Trial in Worldwide (Panzyga, Placebo)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Hypogammaglobulinemia
  • Panzyga
  • Placebo
  • Saint Petersburg, Florida
  • +52 more
Aug 10, 2022

Financial Difficulty in Chronic Lymphocytic Leukemia and

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Plasma Cell Myeloma
  • Medical Chart Review
  • +3 more
  • Anchorage, Alaska
  • +115 more
Aug 2, 2022

Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia Trial in United States (FT819,

Recruiting
  • Lymphoma, B-Cell
  • +2 more
  • Birmingham, Alabama
  • +7 more
Jul 28, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide (Pirtobrutinib, Venetoclax, Rituximab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Phoenix, Arizona
  • +116 more
Jun 27, 2022

Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in United States (FT596, Cyclophosphamide, Fludarabine)

Recruiting
  • Lymphoma, B-Cell
  • Chronic Lymphocytic Leukemia
  • Chicago, Illinois
  • +8 more
Jun 21, 2022

Chronic Lymphocytic Leukemia Trial in Israel, United States (Ublituximab, Ibrutinib)

Completed
Has Results
  • Chronic Lymphocytic Leukemia
  • Huntsville, Alabama
  • +87 more
Apr 25, 2022

Chronic Lymphocytic Leukemia, CLL, SLL Trial in United States (TP-0903, TP-0903 and ibrutinib combination therapy)

Terminated
Has Results
  • Chronic Lymphocytic Leukemia
  • +3 more
  • TP-0903
  • TP-0903 and ibrutinib combination therapy
  • Phoenix, Arizona
  • +5 more
Apr 4, 2022

Chronic Lymphocytic Leukemia, CLL/SLL Trial in New York (Acalabrutinib)

Withdrawn
  • Chronic Lymphocytic Leukemia
  • CLL/SLL
  • New York, New York
    Weill Cornell Medicine
Mar 25, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma Trial in United States (CG-806)

Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Phoenix, Arizona
  • +30 more
Mar 28, 2022